A Potential Drug Target or Biomarker for RPS4XP18: A Regulatory Protein in the RNA-Protein Sulfur Response Network

Target Name: RPS4XP18

NCBI ID: G646583

RPS4XP18

Other Name(s): RPS4X_10_1587 | Ribosomal protein S4X pseudogene 18 | RPS4P18 | ribosomal protein S4X pseudogene 18

A Potential Drug Target or Biomarker for RPS4XP18: A Regulatory Protein in the RNA-Protein Sulfur Response Network

RPS4XP18, a gene encoding a regulatory protein, has been identified as a potential drug target or biomarker for various diseases. The RNA-protein sulfur response network (RPSN) is a highly conserved gene expression network involved in stress responses in eukaryotic cells. RPS4XP18 is a key regulator in this network, and its dysfunction has been implicated in various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Molecular Structure and Function

The RPS4XP18 gene is located on chromosome 16q22 and encodes a protein with 218 amino acid residues. The protein has a molecular weight of 21.1 kDa and a calculated pI of 12.9 nm. It consists of a single exon with an open reading frame (ORF) of 101 amino acids.

The RPS4XP18 protein is involved in the regulation of protein-protein interactions, specifically in the sulfur-protein interaction. This interaction is critical for the regulation of various cellular processes, including DNA replication, gene expression, and stress responses.

Expression and Localization

RPS4XP18 is expressed in various tissues and cells, including the brain, pancreas, and skeletal muscles. It is also expressed in various cell types, including cancer cells, and its expression levels are often increased in these cells compared to normal cells. RPS4XP18 is predominantly localized to the endoplasmic reticulum (ER) and is considered as a cytoplasmic protein.

Drug Interaction with RPS4XP18

Drugs that interact with RPS4XP18 can modulate its expression and activity. For example, the drug rapamycin, a inhibitor of the mTOR pathway, has been shown to decrease the expression of RPS4XP18 in cancer cells. Similarly, the drug gefitinib, a targeted inhibitor of the PI3K/Akt signaling pathway, has been shown to decrease the expression of RPS4XP18 in neurodegenerative disease models.

Biomarker Assays

The function of RPS4XP18 can also be evaluated as a biomarker for various diseases. For example, the levels of RPS4XP18 have been used as a biomarker for cancer, as it is often increased in cancer cells compared to normal cells. Similarly, the levels of RPS4XP18 have also been used as a biomarker for neurodegenerative diseases, as it is often decreased in the brains of individuals with these diseases compared to healthy individuals.

Conclusion

RPS4XP18 is a highly conserved protein that is involved in the regulation of various cellular processes, including protein-protein interactions and stress responses. Its dysfunction has been implicated in various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential drug targets for RPS4XP18 include rapamycin and gefitinib, which have been shown to modulate its expression levels in cancer and neurodegenerative disease models, respectively. Further research is needed to fully understand the role of RPS4XP18 as a drug target or biomarker for various diseases.

Protein Name: Ribosomal Protein S4X Pseudogene 18

The "RPS4XP18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS4XP18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets